 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...125126127128129130131132133134135...235236» |
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Review, Journal: How to Diagnose and Manage Patients With Fluoropyrimidine-Induced Chest Pain: A Single Center Approach. (Pubmed Central) - Aug 17, 2021
No abstract available
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Review, Journal: A totally implantable venous access device (TIVAD) abandoned for 5 years is re-accessed normally: A case report and literature review. (Pubmed Central) - Aug 17, 2021
For the port that has not been used and maintained for a long time up to 5 years, the medical staff should not give up easily. During the COVID-19 pandemic, prolonging the flushing interval of TIVADs can be an optimal clinical strategy without negative outcomes.
- ||| Kanjinti (trastuzumab biosimilar) / Amgen, Daiichi Sankyo, AbbVie
Following up on this discussion: best trials for HER2+ advanced (resected) gallbladder cancer previously treated w/FOLFOX + kanjinti w/some progression? (Twitter) - Aug 17, 2021
- | New P3 trial, Metastases: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) (clinicaltrials.gov) - Aug 16, 2021
P3, N=507, Not yet recruiting, Sponsor: Dominik Paul Modest
- ||||| Clinical: Hi @YJanjigianMD mam .I am from India .My father is a stage 4 stomach cancer patient with peritoneal & omental metastasis .His cancer is pdl1-ve ,Her2neu -ve ,MSI Stable but BRAFV600E +ve.He was already on CAPOX FOLFOX ,Carboplatin ,Etoposide & 5fu , (Twitter) - Aug 16, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Ese es FOLFOX-C 🤟 (Twitter) - Aug 16, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
@DrMedOnco FOLFOX Calderillo (Twitter) - Aug 16, 2021
- | Enrollment open: PANCREAS: PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples (clinicaltrials.gov) - Aug 16, 2021
P2, N=41, Recruiting, Sponsor: Medical College of Wisconsin
During the COVID-19 pandemic, prolonging the flushing interval of TIVADs can be an optimal clinical strategy without negative outcomes. Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Metastases: Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC (clinicaltrials.gov) - Aug 16, 2021
P1, N=60, Enrolling by invitation, Sponsor: Zhejiang Cancer Hospital
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Unavailable now? FOLFIRINOX practically killed my late husband. (Twitter) - Aug 15, 2021
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Trends in treatment patterns among Medicare fee-for-service (FFS) patients receiving treatment for metastatic pancreatic cancer () - Aug 15, 2021 - Abstract #ESMO2021ESMO_3277;
The use of two- and three- line sequences increased consistently from 2016 to 2019. Sequences containing liposomal irinotecan in second and third line are the primary drivers of this increase.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Molecular mechanisms of liver damage during neoadjuvant treatment for hepatic metastases of colorectal cancer. (Pubmed Central) - Aug 15, 2021
Dominant liver damage was by type of SOS syndrome (66.7%), while steatosis of the liver was recorded in only 3.3% of patients. Gender, age, the presence of metabolic syndrome and the number of chemotherapy cycles did not have any statistic significance on the biochemical parameters and morphological degree of liver damage.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. (Pubmed Central) - Aug 15, 2021
Recently, combination strategies involving MAPK pathway blockade have shown promising results in BRAF V600E-mutated mCRC, and other potential targets continue to be explored. In addition, a greater understanding of the role of BRAF V600E mutation in the pathogenesis of CRC should also continue to fuel advances in the management of patients with mCRC harboring this genetic aberration.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
or FOLFOXIRI vs FOLFIRINOX (Twitter) - Aug 15, 2021
- || Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. (Pubmed Central) - Aug 14, 2021
Cytotoxic chemotherapy with platinum doublets such as 5-FU/leucovorin/oxaliplatin is the mainstay of treatment with incremental benefits provided by targeted therapy (trastuzumab, trastuzumab deruxtecan, ramucirumab) and immunotherapy (pembrolizumab, nivolumab)...After reviewing the critical studies that established conventional systemic cytotoxic and targeted therapeutics, we elaborate on recent promising and complex data with immune checkpoint inhibition focusing on implications of tumor histology and PD-L1 expression in the tumor microenvironment. We also highlight novel diagnostic and therapeutic strategies to build on these recent advances.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal: Evaluating the benefit of adjuvant radiotherapy after extensive lymph node dissection for gastric cancer: a single-institute retrospective study. (Pubmed Central) - Aug 14, 2021
Adjuvant RT could improve DFS of patients with locally advanced gastric cancer with or without ELND. When the number of involved lymph nodes is ≥4, adjuvant RT is strongly suggested.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., paclitaxel / Generic mfg.
Journal: Induction FOLFOX and PET-Directed Chemoradiation For Locally Advanced Esophageal Adenocarcinoma. (Pubmed Central) - Aug 14, 2021
When the number of involved lymph nodes is ≥4, adjuvant RT is strongly suggested. Induction FOLFOX followed by PET-directed nCRT may result in better histopathologic response rates and DFS than either induction CP plus PET-directed nCRT or nCRT with CP alone.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. (Pubmed Central) - Aug 14, 2021
In an international cohort of pancreas surgeons, there is substantial variation in management preferences, perceived contraindications to surgery, and the propensity to consider exploration in LAPC. These results emphasize the importance of a robust and nuanced multidisciplinary discussion for each patient, and suggest an evolving concept of "resectability.".
- || pyrimethamine / Generic mfg.
Clinical, PK/PD data, Journal: Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. (Pubmed Central) - Aug 14, 2021
Although pyrimethamine exposure was slightly higher in subjects of Japanese than of European ancestry, a considerable overlap in the range of parameter values was observed. Considering the range of pyrimethamine exposure reported previously, difference in exposure observed in this study would not be considered of note.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. (Pubmed Central) - Aug 14, 2021
This study provides proof of concept that combination of two nano delivery systems can result in successful FOLFOX-associated CRC and HCC therapies. Further optimization in terms of dosing and timing will enhance clinical potential of this combination strategy for patients.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Yes, more taxane after just having taxane failure doesn’t make much sense. I too have seen FOLFIRI-ram work well for a while after FLOT failure. (Twitter) - Aug 14, 2021
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Anecdotally, I have seen some great responses to FOLFIRI-Ram in tumors that progressed after FLOT. Makes me think about tumor-specific susceptibilities worth exploring. These are drugs in our toolbox... we need to understand why and when they work. New drugs are great... but geez (Twitter) - Aug 13, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
I agree @JeremyLDavisMD. IO is not going to work here in this scenario that is all too common (from trial data and experience) @doctorC369 It’s FOLFIRI-ram or IP or other trial here in this scenario for me. (Twitter) - Aug 13, 2021
- |||| Braftovi (encorafenib) / Pfizer
New P2 trial, Metastases: NAUTICALCRC: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (clinicaltrials.gov) - Aug 12, 2021
P2, N=103, Not yet recruiting, Sponsor: Pierre Fabre Medicament
- | Fruzaqla (fruquintinib) / Takeda
New P2 trial, Metastases: Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 12, 2021
P2, N=43, Recruiting, Sponsor: Zhou Fuxiang
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: 1 series of vaccine vs 6 months FOLFOX or Folfirinox. Who comes up with this shit? (Twitter) - Aug 12, 2021
- |||||||| New P3 trial: Survival analysis after pre-surgical therapy in patients with resectable pancreatic cancer and risk factors AN (EUDRACT) - Aug 12, 2021
P3, N=116, Ongoing, Sponsor: Fundaci
- | Trial completion, Metastases: SEQUENCE: Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 12, 2021
P1/2, N=168, Completed, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Further optimization in terms of dosing and timing will enhance clinical potential of this combination strategy for patients. Active, not recruiting --> Completed
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal, Real-world evidence: Hospitalizations among early-stage colon cancer patients receiving adjuvant chemotherapy: a real-world study. (Pubmed Central) - Aug 12, 2021
In this study, one out of five colon cancer patients were hospitalized during adjuvant chemotherapy. Older individuals, women, those with higher comorbidity, and those receiving adjuvant CAPOX were more likely to be hospitalized.
- || nadunolimab (CAN04) / Cantargia
Enrollment open, Combination therapy, Metastases: CAPAFOUR: A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Aug 11, 2021
P1b, N=30, Recruiting, Sponsor: Cantargia AB
Older individuals, women, those with higher comorbidity, and those receiving adjuvant CAPOX were more likely to be hospitalized. Not yet recruiting --> Recruiting
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
I would continue with FOLFOX. (Twitter) - Aug 11, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Do not fight with success. Complete FOLFOX (Twitter) - Aug 11, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
FOLFOX >Gem/Cape, but second @SyedMAhmedMDPhD consideration of sensitizing. Also, sequence the tissue (mainly for the surprise fusions, etc). (Twitter) - Aug 11, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
To continue FOLFOX (Twitter) - Aug 11, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Agree with continuing FOLFOX (Twitter) - Aug 11, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Missed the beginning of the 🧵- agree to finish with FOLFOX (Twitter) - Aug 11, 2021
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
With tumor response, that’s enough for me. Finish with FOLFOX (Twitter) - Aug 11, 2021
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Have to agree with the group... cont with FOLFOX, esp if the neuropathy is a non issue because of the break for surgery (Twitter) - Aug 11, 2021
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Clinical: Agree with FOLFOX, would spare Gemcitabine in case of progression and clinical trial would likely include that option (Twitter) - Aug 11, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Con't FOLFOX IMO (Twitter) - Aug 11, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
FOLFOX (Twitter) - Aug 11, 2021
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Perhaps, if the CA 19-9 responded neoadj to FOLFOX and evidence or pathologic response to FOLFOX, seems reasonable to complete FOLFOX postoperatively. Would be worried that exposing residual tumor cells to more agents could lead to resistant clones. (Twitter) - Aug 11, 2021
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: 🙋need an advice #medtwitter #Patient with resectable #PancreaticCancer, neoadj FFX, allergic reaction to IRI, continued è FOLFOX X 3 mos. surgery, -ve margins, 2+LN, tumor response. Would you continue FOLFOX or change to Gem/Cap? @OncoAlert @EileenMOReilly #PCSM @PancSMChat (Twitter) - Aug 11, 2021
- || irinotecan / Generic mfg.
Review, Journal, PARP Biomarker: Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma. (Pubmed Central) - Aug 11, 2021
Although systemic therapies have become more potent with the development of fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel as first-line treatments, the median overall survival for patients treated with either of these regimens remains just above 1 year...We believe clinical trials should be considered early for mPDA patients, in all treatment lines, so that novel therapies may be added to the treatment armamentarium for patients with this disease. Beyond NGS testing from tumor tissue, we believe it is important to consider germline genetic testing for all patients diagnosed with PDA given recent data suggesting a much stronger hereditary component of the disease than previously understood, and the potential screening implications for family members.
- || cisplatin / Generic mfg.
Review, Journal, IO biomarker: New Treatment Options for Advanced Biliary Tract Cancer. (Pubmed Central) - Aug 11, 2021
Based on the promising results of a phase II study, an ongoing multi-institutional phase III study is assessing the benefit of adding nab-paclitaxel to the chemotherapy doublet, and appropriate patients should be considered for enrollment at participating centers...If a targetable fusion or mutation is not detected, patients eligible for second-line therapy should be considered for either clinical trial enrollment or a second-line cytotoxic chemotherapy regimen such as modified FOLFOX. Strategies incorporating immunotherapy into the treatment of patients with microsatellite stable advanced biliary tract cancers have yielded largely disappointing results thus far, and routine use of checkpoint inhibitors outside of a clinical trial is not recommended.
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: Contemporary management of pancreas cancer in older people. (Pubmed Central) - Aug 11, 2021
Palliative chemotherapy options are FOLFIRINOX or gemcitabine/nab-paclitaxel for patients with good performance status (0-1) and gemcitabine alone for patients with performance status 2-3...The presence of geriatricians in the multidisciplinary team meetings is crucial in order to identify the optimal treatment pathway for elderly patients. Geriatric input regarding peri-habilitation pathways to improve surgical outcomes, to decrease mortality and to expedite patients' functional recovery is highly recommended.
- | remdesivir / Generic mfg., methotrexate / Generic mfg.
Preclinical, Journal: The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. (Pubmed Central) - Aug 11, 2021
Firstly, its previously known ability to reduce aberrant inflammatory responses might dampen respiratory distress. In addition, its direct antiviral activity described here would limit the dissemination of the virus.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Review, Journal: Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. (Pubmed Central) - Aug 10, 2021
While traditionally emphasized in selecting targeted therapies based on molecular, genetic, and radiographic biomarkers for patients with metastatic disease, the neoadjuvant setting is a prime opportunity to utilize personalized approaches. In this article, we describe the current evidence for the use of neoadjuvant therapy (NT) and highlight unique opportunities for personalized care in patients with PDAC undergoing NT.
- |||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Aug 9, 2021
P2, N=58, Not yet recruiting, Sponsor: National Cheng-Kung University Hospital
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal, PD(L)-1 Biomarker, IO biomarker: Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. (Pubmed Central) - Aug 8, 2021
This study investigates the effect of 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (FOLFIRINOX), and gemcitabine plus nab-paclitaxel (GEMnPAC) regimens on PD-L1 mRNA expression in plasma-derived microvesicles (MVs) in 50 PDAC patients...The increase in PD-L1 mRNA expression in MVs was not related to tumor response (PR + SD: p = 0.08; PD: p = 0.28). Our findings demonstrate that GEMnPAC can increase PD-L1 mRNA expression in patient-derived circulating MVs, providing a rationale for testing the efficacy of this regimen in sequential or simultaneous combinations with immunotherapy in PDAC patients.